Opinion|Videos|July 8, 2024
Hidradenitis Suppurativa: Addressing the Psychosocial Impact and Hospitalization Rate
Author(s)Iltefat Hamzavi, MD
Dr Hamzavi discusses how clinicians can address the psychosocial impact of hidradenitis suppurativa on patients and the rate of hospitalization.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What is the psychosocial impact of HS and how can clinicians empower these patients?
- How is the rate of hospitalization due to HS changing over time and what can clinicians do to keep patients out of the hospital?
- How is the rate of hospitalization due to HS changing over time and what can clinicians do to keep patients out of the hospital?
Advertisement
Related to this article
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Multi-Hit TP53 Linked to Shorter Survival in Chronic-Phase MPN Cohorts
4
Navigating GLP-1 Access & Prior Authorizations: Amanda Velazquez, MD
5